Thrivent Financial For Lutherans increased its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 7.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 21,610 shares of the company’s stock after buying an additional 1,460 shares during the period. Thrivent Financial For Lutherans’ holdings in Amphastar Pharmaceuticals were worth $386,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently modified their holdings of AMPH. Dimensional Fund Advisors LP lifted its position in Amphastar Pharmaceuticals by 32.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,061,188 shares of the company’s stock worth $15,388,000 after buying an additional 260,288 shares in the last quarter. State Street Corp lifted its position in Amphastar Pharmaceuticals by 11.1% during the 1st quarter. State Street Corp now owns 1,062,439 shares of the company’s stock worth $15,406,000 after buying an additional 106,448 shares in the last quarter. Bank of Montreal Can lifted its position in Amphastar Pharmaceuticals by 1,032.9% during the 2nd quarter. Bank of Montreal Can now owns 69,649 shares of the company’s stock worth $1,244,000 after buying an additional 63,501 shares in the last quarter. Bank of New York Mellon Corp lifted its position in Amphastar Pharmaceuticals by 11.4% during the 1st quarter. Bank of New York Mellon Corp now owns 519,802 shares of the company’s stock worth $7,536,000 after buying an additional 53,214 shares in the last quarter. Finally, Fisher Asset Management LLC lifted its position in Amphastar Pharmaceuticals by 29.5% during the 2nd quarter. Fisher Asset Management LLC now owns 195,547 shares of the company’s stock worth $3,492,000 after buying an additional 44,492 shares in the last quarter. Institutional investors and hedge funds own 44.26% of the company’s stock.
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) opened at 18.45 on Friday. The company’s 50-day moving average is $17.19 and its 200 day moving average is $16.41. The firm has a market cap of $852.30 million, a P/E ratio of 239.61 and a beta of 1.69. Amphastar Pharmaceuticals, Inc. has a 12 month low of $12.05 and a 12 month high of $21.75.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings results on Wednesday, August 9th. The company reported $0.11 EPS for the quarter, beating the Zacks’ consensus estimate of $0.06 by $0.05. Amphastar Pharmaceuticals had a return on equity of 2.42% and a net margin of 1.61%. The firm had revenue of $65.20 million for the quarter, compared to analyst estimates of $63.40 million. During the same period last year, the firm posted $0.23 earnings per share. The business’s revenue for the quarter was down 4.1% on a year-over-year basis. Equities research analysts expect that Amphastar Pharmaceuticals, Inc. will post $0.27 EPS for the current fiscal year.
Amphastar Pharmaceuticals declared that its board has approved a share buyback program on Wednesday, August 9th that authorizes the company to repurchase $20.00 million in outstanding shares. This repurchase authorization authorizes the company to purchase up to 2.8% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s board of directors believes its shares are undervalued.
In related news, Director Stephen B. Shohet sold 7,862 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Thursday, October 19th. The stock was sold at an average price of $18.34, for a total value of $144,189.08. Following the transaction, the director now directly owns 31,978 shares of the company’s stock, valued at $586,476.52. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Diane G. Gerst sold 8,444 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Thursday, October 5th. The stock was sold at an average price of $18.87, for a total value of $159,338.28. The disclosure for this sale can be found here. Insiders have sold 145,653 shares of company stock worth $2,626,205 over the last three months. Insiders own 11.10% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Thrivent Financial For Lutherans Raises Position in Amphastar Pharmaceuticals, Inc. (AMPH)” was first published by Stock Observer and is the sole property of of Stock Observer. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://www.thestockobserver.com/2017/10/20/thrivent-financial-for-lutherans-raises-position-in-amphastar-pharmaceuticals-inc-amph.html.
AMPH has been the topic of several research reports. TheStreet upgraded shares of Amphastar Pharmaceuticals from a “c” rating to a “b-” rating in a research report on Monday, June 26th. Wells Fargo & Company reiterated a “buy” rating on shares of Amphastar Pharmaceuticals in a research report on Saturday, July 22nd. Piper Jaffray Companies set a $20.00 price target on shares of Amphastar Pharmaceuticals and gave the stock a “buy” rating in a research report on Saturday, July 29th. BMO Capital Markets reiterated a “hold” rating and set a $16.00 price target on shares of Amphastar Pharmaceuticals in a research report on Monday, July 31st. Finally, BidaskClub downgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, July 28th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $20.29.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.